James Richardson, Ph.D.

James Richardson is Associate Professor of Management at the Shidler College of Business at the University of Hawaii at Manoa where he teaches entrepreneurship and strategy. Recent research projects have looked at social networks around venture capital in China, international variation in institutional support for entrepreneurship, and business models in strategy execution. He has published articles in Strategic Management Journal, Organization Science, and other leading management journals. He received his PhD from the Wharton School at The University of Pennsylvania, an SM in operations research from MIT, and a BA from the University of Hawaii. An avid surfer, he lives on the North Shore of Oahu where he runs Surflight Hawaii, a surfboard manufacturer based on a patented high performance soft surfboard technology.

Recent Reviews All Reviews

How to Lose $6 Billion

Nuclear power looked like a promising business when Toshiba acquired Westinghouse Electric in 2006. Now cost overruns and delays at the only nuclear plants under construction in the United States since 1979 will cripple, if not bankrupt, the once formidable industrial conglomerate.


Trump’s talk of hard line dealing with China over trade has Hollywood worried. The Chinese had promised to further open their lucrative film market this year, and Hollywood doesn’t want anything to change their minds.

Can Sneaker Makers Come Home Again?

Athletic footwear makers may bring some manufacturing back to the United States to save on shipping and perhaps avoid a Trump Twitter tirade. But the factories are likely to be highly automated and create few jobs.

Spread Your Wings and Fly, Penguin

The printed book is dead, long live the printed book. Bertelsmann is betting that print books will continue to be good business as it moves to take 100 percent ownership of Penguin, the world’s largest book publisher.

Pharma's Worst Nightmare

Celebration of Trump’s victory by pharmaceutical executives turned to fear when he suggested they should bid for the government’s business as well as bring manufacturing back to the U.S. But Trump will have to overcome the powerful pharmaceutical lobby to get such measures through the Republican Congress.